# US 2013/0156695 A1 · Use of zcytor17 ligand antagonists for treating inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156695 A1
- Document ID: US20130156695A1
- Status: Published application
- Kind: A1
- Application number: 13/359,049
- Filed: 2012-01-26
- Published: 2013-06-20
- Earliest claimed: 2002-01-18
- Assignees: ZymoGenetics, Inc.
- Inventors: Cindy A. Sprecher; Joseph L. Kuijper; Maria M. Dasovich; Francis J. Grant; Jane A. Gross; Angela K. Hammond
- Web page: https://patentgrep.com/patent/US20130156695A1

## CPC

- C07K 16/24: against cytokines, lymphokines or interferons
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/47: from mammals
- C07K 14/52: Cytokines; Lymphokines; Interferons
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

## Claims

### Claim 1

A method of treating an inflammatory disease in a mammal comprising administering to the mammal a therapeutically effective amount of an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2, wherein the inflammatory disease is selected from the group consisting of atopic dermatitis, inflammatory bowel disease, ulcerative colitis, Crohn's disease and eczema.

### Claim 2 (depends on 1)

The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is humanized.

### Claim 3 (depends on 1)

The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is human.

### Claim 4 (depends on 1)

The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof reduces the binding of the polypeptide to its receptor.

### Claim 5 (depends on 4)

The method of claim 4, wherein the monoclonal antibody or antigen-binding fragment thereof reduces the signal transduction in the cell expressing the receptor.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antigen-binding fragment is a F(ab′)2, Fab or a single chain Fv.

### Claim 7 (depends on 1)

The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin.

### Claim 8 (depends on 1)

The method of claim 1, wherein the inflammatory disease is atopic dermatitis.

### Claim 9 (depends on 1)

The method of claim 1, wherein the inflammatory disease is inflammatory bowel disease.

### Claim 10 (depends on 1)

The method of claim 1, wherein the inflammatory disease is ulcerative colitis.

### Claim 11 (depends on 1)

The method of claim 1, wherein the inflammatory disease is Crohn's disease.

### Claim 12 (depends on 1)

The method of claim 1, wherein the inflammatory disease is eczema.

### Claim 13

A method of treating an inflammatory disease in a mammal comprising administering to the mammal a therapeutically effective amount of a composition comprising an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2, and a pharmaceutically acceptable carrier, wherein the inflammatory disease is selected from the group consisting of atopic dermatitis, inflammatory bowel disease, ulcerative colitis, Crohn's disease and eczema.

### Claim 14 (depends on 13)

The method of claim 13, wherein the monoclonal antibody or antigen-binding fragment thereof is humanized.

### Claim 15 (depends on 13)

The method of claim 13, wherein the monoclonal antibody or antigen-binding fragment thereof is human.

### Claim 16 (depends on 13)

The method of claim 13, wherein the monoclonal antibody or antigen-binding fragment thereof reduces the binding of the polypeptide to its receptor.

### Claim 17 (depends on 16)

The method of claim 16, wherein the monoclonal antibody or antigen-binding fragment thereof reduces the signal transduction in the cell expressing the receptor.

### Claim 18 (depends on 13)

The method of claim 13, wherein the antigen-binding fragment is a F(ab′)2, Fab or a single chain Fv.

### Claim 19 (depends on 13)

The method of claim 13, wherein the monoclonal antibody or antigen-binding fragment thereof further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin.

### Claim 20 (depends on 13)

The method of claim 13, wherein the inflammatory disease is atopic dermatitis.

### Claim 21 (depends on 13)

The method of claim 13, wherein the inflammatory disease is inflammatory bowel disease.

### Claim 22 (depends on 13)

The method of claim 13, wherein the inflammatory disease is ulcerative colitis.

### Claim 23 (depends on 13)

The method of claim 13, wherein the inflammatory disease is Crohn's disease.

### Claim 24 (depends on 13)

The method of claim 13, wherein the inflammatory disease is eczema.
